Orchestra BioMed (OBIO) to Release Quarterly Earnings on Monday

Key Points

• Orchestra BioMed will report Q1 2026 results before the market opens on Monday, May 11, 2026, with analysts expecting roughly ($0.40) EPS and about $0.919M in revenue.
• In the prior quarter (reported March 12) the company posted a surprising beat — $0.26 EPS and $30.92M revenue — but still showed a very negative net margin and return on equity, while analysts forecast roughly -2 EPS for the current fiscal year and -1 EPS next year.
• OBIO shares traded up ~3.8% to $4.12, the company has a market cap around $246.7M, an insider recently bought 10,000 shares, institutional investors own ~53.2%, and the Street’s consensus price target is about $14.25 (average rating: Moderate Buy).

Orchestra BioMed (NASDAQ:OBIO - Get Free Report) is expected to be issuing its Q1 2026 results before the market opens on Monday, May 11th. Analysts expect the company to announce earnings of ($0.40) per share and revenue of $0.9190 million for the quarter. Parties are encouraged to explore the company's upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Monday, May 11, 2026 at 4:00 PM ET.

Orchestra BioMed (NASDAQ:OBIO - Get Free Report) last posted its quarterly earnings data on Thursday, March 12th. The company reported $0.26 earnings per share for the quarter, topping the consensus estimate of ($0.38) by $0.64. Orchestra BioMed had a negative net margin of 157.40% and a negative return on equity of 184.17%. The firm had revenue of $30.92 million during the quarter, compared to analysts' expectations of $0.93 million. On average, analysts expect Orchestra BioMed to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Orchestra BioMed Trading Up 3.8%

OBIO stock traded up $0.15 during trading on Monday, hitting $4.12. The company had a trading volume of 28,637 shares, compared to its average volume of 200,396. The company has a quick ratio of 6.43, a current ratio of 6.45 and a debt-to-equity ratio of 0.27. The firm has a 50-day moving average price of $4.34 and a 200-day moving average price of $4.25. Orchestra BioMed has a 12 month low of $2.20 and a 12 month high of $5.42. The stock has a market cap of $246.71 million, a price-to-earnings ratio of -3.64 and a beta of 0.52.

Insider Activity

In other news, insider David P. Hochman purchased 10,000 shares of the firm's stock in a transaction dated Friday, March 13th. The stock was bought at an average price of $4.29 per share, with a total value of $42,900.00. Following the acquisition, the insider directly owned 1,086,467 shares of the company's stock, valued at approximately $4,660,943.43. This represents a 0.93% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 8.10% of the stock is owned by company insiders.

Hedge Funds Weigh In On Orchestra BioMed

Several institutional investors and hedge funds have recently made changes to their positions in OBIO. Alyeska Investment Group L.P. acquired a new position in shares of Orchestra BioMed in the 3rd quarter valued at $3,386,000. Pathstone Holdings LLC acquired a new position in shares of Orchestra BioMed in the 3rd quarter valued at $2,495,000. Vanguard Group Inc. grew its holdings in shares of Orchestra BioMed by 28.0% in the 3rd quarter. Vanguard Group Inc. now owns 1,481,875 shares of the company's stock valued at $3,675,000 after buying an additional 324,558 shares during the period. Marshall Wace LLP acquired a new position in shares of Orchestra BioMed in the 4th quarter valued at $712,000. Finally, Goldman Sachs Group Inc. grew its holdings in shares of Orchestra BioMed by 467.4% in the 4th quarter. Goldman Sachs Group Inc. now owns 134,073 shares of the company's stock valued at $556,000 after buying an additional 110,443 shares during the period. Institutional investors and hedge funds own 53.20% of the company's stock.

Wall Street Analysts Forecast Growth

OBIO has been the subject of several research analyst reports. Barclays boosted their price objective on shares of Orchestra BioMed from $11.00 to $12.00 and gave the stock an "overweight" rating in a research report on Friday, January 9th. Weiss Ratings lowered shares of Orchestra BioMed from a "sell (d-)" rating to a "sell (e+)" rating in a report on Tuesday, April 21st. Wall Street Zen raised shares of Orchestra BioMed from a "strong sell" rating to a "hold" rating in a report on Saturday, March 14th. Finally, Chardan Capital reaffirmed a "buy" rating and set a $20.00 target price on shares of Orchestra BioMed in a report on Thursday, March 12th. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Orchestra BioMed currently has an average rating of "Moderate Buy" and a consensus price target of $14.25.

About Orchestra BioMed

Orchestra BioMed, Inc NASDAQ: OBIO is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies for inflammatory, fibrotic and oncologic diseases. The company's research focuses on novel small-molecule programs designed to address high‐unmet-need conditions by leveraging proprietary prodrug and targeted inhibitor platforms. Orchestra BioMed's pipeline includes lead candidates such as OBI-3424, a prodrug activated by AKR1C3 for the treatment of select solid tumors, and next-generation modulators aimed at suppressing pathological inflammation and fibrosis.

Orchestra BioMed conducts early‐ and mid-stage clinical studies in North America, working closely with key opinion leaders and academic centers to advance its programs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.